# Ana M. González-Angulo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ana-m-gonzalez-angulo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,935 |
| Field | Breast Cancer Treatment Studies |
| h-index | 102 |
| i10-index | 221 |
| OpenAlex ID | https://openalex.org/A5073488441 |
| ORCID iD | https://orcid.org/0000-0002-9816-2707 |
| Works | 716 |

## Researcher papers

- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple/)
- [Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes](https://scholariq.org/papers/invasive-lobular-carcinoma-classic-type-response-to-primary-chemotherapy-and/)
- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple-2/)
- [PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors](https://scholariq.org/papers/pik3ca-pten-mutations-and-akt-activation-as-markers-of-sensitivity-to-allosteric/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.